公开(公告)号：US20140073700A1

公开(公告)日：2014-03-13

申请号：US14023143

申请日：2013-09-10

Applicant: AbbVie Inc.

Inventor： Rolf Wagner ,  Hui-Ju Chen ,  Jason Shanley ,  Andrew Bogdan ,  Jasmina Marjanovic ,  Xiu Wang ,  Diana Donnelly-Roberts

IPC: C07C261/00

CPC classification number: C07C261/00 ,  C07J63/008

Abstract: The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Y and Z are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.

Abstract translation: 本申请涉及：（a）式（I）的化合物及其盐，其中Y和Z如说明书中所定义; （b）包含这些化合物和盐的组合物; 和（c）使用这些化合物，盐和组合物的方法，特别用于治疗和预防与氧化应激和炎症有关的疾病。

公开(公告)号：US20250145587A1

公开(公告)日：2025-05-08

申请号：US18733551

申请日：2024-06-04

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Steven Fidanze ,  Keith McDaniel ,  John Pratt ,  Le Wang

IPC: C07D401/12 ,  C07D213/64 ,  C07D401/04

Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, X1, X2, R2, R3, R4, R5, R6, and m have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

公开(公告)号：US20250122160A1

公开(公告)日：2025-04-17

申请号：US18647757

申请日：2024-04-26

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Philip R. Kym ,  Jennifer M. Frost ,  Christos Economou ,  Andrew Bogdan ,  Stacy Fosu ,  Zhaoming Xiong ,  Spencer O. Scholz ,  Eric Allan Voight ,  Elliot P. Farney ,  Mark A. Matulenko ,  Matthew J. O'Connor ,  Christina Baumgartner ,  Qingwei Zhang ,  Reza Shiroodi ,  Jason R. Abbott ,  Geoff T. Halvorsen

IPC: C07D285/06 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/501 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

公开(公告)号：US20230019236A1

公开(公告)日：2023-01-19

申请号：US17807292

申请日：2022-06-16

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Elliot P. Farney ,  Reza Shiroodi ,  Zhaoming Xiong ,  Qingwei Zhang ,  Matthew J. O'Connor ,  Geoff T. Halvorsen ,  Hongyu Zhao ,  Christina Baumgartner ,  Jennifer M. Frost ,  Philip R. Kym ,  Jason R. Abbott ,  Andrew Bogdan ,  Christos Economou ,  Xueqing Wang

IPC: A61K31/433 ,  A61K39/395 ,  A61P35/00 ,  C07D417/10 ,  A61K31/5377 ,  C07D285/06

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

公开(公告)号：US20210253551A1

公开(公告)日：2021-08-19

申请号：US17100045

申请日：2020-11-20

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Steven Fidanze ,  Keith McDaniel ,  John Pratt ,  Le Wang

IPC: C07D401/12 ,  C07D213/64 ,  C07D401/04

Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, X1, X2, R2, R3, R4, R5, R6, and m have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

公开(公告)号：US20190008866A1

公开(公告)日：2019-01-10

申请号：US16117203

申请日：2018-08-30

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Warren M. Kati ,  Keith F. McDaniel ,  Chang H. Park ,  George S. Sheppard ,  Le Wang

IPC: A61K31/506 ,  C07D487/04 ,  A61K31/4412 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  C07D211/86 ,  C07D213/69 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  A61K31/444 ,  C07D417/12

Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20180298003A1

公开(公告)日：2018-10-18

申请号：US16018357

申请日：2018-06-26

Applicant: AbbVie Inc.

Inventor： Steven D. Fidanze ,  Dachun Liu ,  Robert A. Mantei ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Le Wang ,  Andrew Bogdan ,  James H. Holms ,  Justin D. Dietrich ,  Jasmina Marjanovic ,  Lisa A. Hasvold ,  Yujia Dai

IPC: C07D471/22 ,  C07D471/16

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

公开(公告)号：US10085985B2

公开(公告)日：2018-10-02

申请号：US15216855

申请日：2016-07-22

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Warren M. Kati ,  Keith F. McDaniel ,  Chang H. Park ,  George S. Sheppard ,  Le Wang

IPC: A61K31/506 ,  C07D487/04 ,  C07D211/86 ,  C07D405/04 ,  C07D401/04 ,  C07D417/04 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D213/69 ,  A61K31/4412 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497

Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US09969693B2

公开(公告)日：2018-05-15

申请号：US15239554

申请日：2016-08-17

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC: C07D215/48 ,  C07D401/12 ,  C07D409/14 ,  C07D487/08 ,  C07D401/14 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20160331749A1

公开(公告)日：2016-11-17

申请号：US15216855

申请日：2016-07-22

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Warren M. Kati ,  Keith F. McDaniel ,  Chang H. Park ,  George S. Sheppard ,  Le Wang

IPC: A61K31/506 ,  A61K31/4433 ,  A61K31/497 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4412 ,  A61K31/4439

CPC classification number: A61K31/506 ,  A61K31/4412 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  C07D211/86 ,  C07D213/69 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D487/04

Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract translation: 其中Y1，Y2，R1，R2，R3，A1，A2，A3和A4具有说明书中定义的任何值及其药学上可接受的盐，其可用作治疗疾病和病症的试剂，包括 炎性疾病，癌症和艾滋病。 还提供了由一种或多种式（I）化合物组成的药物组合物。